Of the natural compounds that demonstrated potent anti-tumor activity in both NF-related models, the eIF4A inhibitors rocaglamide and didesmethylrocaglamide effectively block the expression multiple oncogenic kinases with good bioavailability and toxicity profiles and are expected to enter clinical trials in the future. Here, EIF4A1 is linked to neoplasm.